GLAXOSMITHKLINE

  • Ebola vaccine will not be ready until March: WHO October 2, 2014

    Geneva: Two vaccines that give preliminary indications of providing effective and reliable immunization against the deadly Ebola virus ravaging West Africa will not be ready for testing until next March, the World Health Organization (WHO) said. Developing a vaccine usually takes time and is expensive, the WHO said. "Even in best conditions...
  • GlaxoSmithKline aims to market world's first malaria vaccine October 8, 2013

    British drugmaker GlaxoSmithKline will seek marketing approval for the world's first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children. The vaccine known as RTS,S was found, after 18 months of followup, to have almost halved the number of malaria cases...
  • Glaxo settles healthcare fraud case for $3 billion July 3, 2012

    Washington: GlaxoSmithKline Plc agreed to plead guilty to misdemeanor criminal charges and pay $3 billion to settle what government officials on Monday described as the largest case of healthcare fraud in US history. The agreement, which still needs court approval, would resolve allegations that the British drugmaker broke US laws in...
  • GSK faces Q4 profit wipeout on $3 billion legal hit January 18, 2011

    London: GlaxoSmithKline will record a legal charge of 2.2 billion pounds ($3.4 billion) for the fourth quarter, effectively wiping out its profit, as it settles further claims related to Avandia and sales practices. The charge equates to an aftertax cost of 1.8 billion pounds, more than the 1.45 billion the...
  • GSK offers UK rebate against Pfizer drug December 24, 2010

    London: Britain's staterun health service will get a partial rebate from GlaxoSmithKline if the company's new kidney cancer drug Votrient does not match up to a rival medicine in a headtohead clinical trial. The unusual deal, the first of its kind, hints at the type of complex arrangements that could become...
  • Diabetes drug may be bad for heart: Report February 21, 2010

    An internal report by the US Food and Drug Administration has said that common diabetes drug Rosiglitazone comes with a risk of heart attacks. Sold by GSK under the name Avandia, the drug reportedly causes fluid retention. A US Senate report has alleged that drugmaker GlaxoSmithKline knew of the risks....
  • Business pays for Telangana row December 11, 2009

    Mumbai: A unit of global drugmaker GlaxoSmithKline temporarily halted operations in Andhra Pradesh on Friday as the fallout from a government plan to carve up the southern state mounted. The government approved a plan on Thursday to create a new state called Telangana out of Andhra Pradesh after more than a...